Literature DB >> 31081673

Thyroid and Cardiovascular Disease Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Anne R Cappola1, Akshay S Desai2, Marco Medici3, Lawton S Cooper4, Debra Egan5, George Sopko4, Glenn I Fishman6, Steven Goldman7, David S Cooper8, Samia Mora9, Peter J Kudenchuk10, Anthony N Hollenberg11, Cheryl L McDonald4, Paul W Ladenson8.   

Abstract

Thyroid hormones have long been known to have a range of effects on the cardiovascular system. However, significant knowledge gaps exist concerning the precise molecular and biochemical mechanisms governing these effects and the optimal strategies for management of abnormalities in thyroid function in patients with and without preexisting cardiovascular disease. In September 2017, the National Heart, Lung, and Blood Institute convened a Working Group with the goal of developing priorities for future scientific research relating thyroid dysfunction to the progression of cardiovascular disease. The Working Group reviewed and discussed the roles of normal thyroid physiology, the consequences of thyroid dysfunction, and the effects of therapy in 3 cardiovascular areas: cardiac electrophysiology and arrhythmias, the vasculature and atherosclerosis, and the myocardium and heart failure. This report describes the current state of the field, outlines barriers and challenges to progress, and proposes research opportunities to advance the field, including strategies for leveraging novel approaches using omics and big data. The Working Group recommended research in 3 broad areas: (1) investigation into the fundamental biology relating thyroid dysfunction to the development of cardiovascular disease and into the identification of novel biomarkers of thyroid hormone action in cardiovascular tissues; (2) studies that define subgroups of patients with thyroid dysfunction amenable to specific preventive strategies and interventional therapies related to cardiovascular disease; and (3) clinical trials focused on improvement in cardiovascular performance and cardiovascular outcomes through treatment with thyroid hormone or thyromimetic drugs.

Entities:  

Keywords:  low T3 syndrome; subclinical hyperthyroidism; subclinical hypothyroidism

Year:  2019        PMID: 31081673      PMCID: PMC6851449          DOI: 10.1161/CIRCULATIONAHA.118.036859

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  121 in total

1.  Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver-selective thyroid hormone receptor agonist eprotirome.

Authors:  Bo Angelin; Jens D Kristensen; Mats Eriksson; Bo Carlsson; Irwin Klein; Anders G Olsson; E Chester Ridgway; Paul W Ladenson
Journal:  J Intern Med       Date:  2014-05-16       Impact factor: 8.989

2.  Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease.

Authors:  Stig Andersen; Klaus Michael Pedersen; Niels Henrik Bruun; Peter Laurberg
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

3.  The significance of alterations in serum lipids in thyroid dysfunction. I. The relation between serum lipoproteins, carotenoids and vitamin A in hypothyroidism and thyrotoxicosis.

Authors:  K W Walton; D A Campbell; E L Tonks
Journal:  Clin Sci       Date:  1965-10       Impact factor: 6.124

4.  Pulmonary hypertension is frequent in hyperthyroidism and normalizes after therapy.

Authors:  Maurizio Marvisi; Paolo Zambrelli; Marco Brianti; Giuseppe Civardi; Rinaldo Lampugnani; Roberto Delsignore
Journal:  Eur J Intern Med       Date:  2006-07       Impact factor: 4.487

5.  Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism.

Authors:  Grzegorz Kaminski; Dariusz Michalkiewicz; Karol Makowski; Zbigniew Podgajny; Norbert Szalus; Marek Ruchala; Ewelina Szczepanek; Grzegorz Gielerak
Journal:  Clin Endocrinol (Oxf)       Date:  2011-04       Impact factor: 3.478

6.  Long-term amiodarone administration remodels expression of ion channel transcripts in the mouse heart.

Authors:  Sabrina Le Bouter; Aziza El Harchi; Céline Marionneau; Chloé Bellocq; Arnaud Chambellan; Toon van Veen; Christophe Boixel; Bruno Gavillet; Hugues Abriel; Khai Le Quang; Jean-Christophe Chevalier; Gilles Lande; Jean J Léger; Flavien Charpentier; Denis Escande; Sophie Demolombe
Journal:  Circulation       Date:  2004-11-01       Impact factor: 29.690

7.  Dyslipidemia in subclinical hypothyroidism requires assessment of small dense low density lipoprotein cholesterol (sdLDL-C).

Authors:  Maida Seferovic Saric; Miljenka-Jelena Jurasic; Slavica Sovic; Bojana Kranjcec; Tatjana Glivetic; Vida Demarin
Journal:  Rom J Intern Med       Date:  2017-09-26

Review 8.  Amiodarone and the thyroid.

Authors:  Shehzad Basaria; David S Cooper
Journal:  Am J Med       Date:  2005-07       Impact factor: 4.965

9.  Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality.

Authors:  Salman Razvi; Jolanta U Weaver; Timothy J Butler; Simon H S Pearce
Journal:  Arch Intern Med       Date:  2012-05-28

Review 10.  Multi-omics approaches to disease.

Authors:  Yehudit Hasin; Marcus Seldin; Aldons Lusis
Journal:  Genome Biol       Date:  2017-05-05       Impact factor: 13.583

View more
  10 in total

1.  Economic and Cardiometabolic Risk Factors Are Predictors of Lower Thyroid Stimulating Hormone (TSH) Levels in Hispanic/Latinx Adults with Euthyroidism-A Community-Based Study.

Authors:  Sabrina Sales Martinez; Margaret Gutierrez; Ivan Delgado-Enciso; Jezabel Maisonet; Aydevis Jean Pierre; Adriana Campa; Laura Kallus; Janet Diaz Martinez
Journal:  Int J Environ Res Public Health       Date:  2022-07-02       Impact factor: 4.614

Review 2.  Pro-Arrhythmic Signaling of Thyroid Hormones and Its Relevance in Subclinical Hyperthyroidism.

Authors:  Narcis Tribulova; Lin Hai Kurahara; Peter Hlivak; Katsuya Hirano; Barbara Szeiffova Bacova
Journal:  Int J Mol Sci       Date:  2020-04-19       Impact factor: 5.923

3.  Prevalence and Risk Factors of Left Ventricular Diastolic Dysfunction in Patients With Hyperthyroidism.

Authors:  Huan Li; Renli Zeng; Yunfei Liao; Mengfei Fu; Huan Zhang; Linfang Wang; Yuming Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-08       Impact factor: 5.555

4.  Machine Learning Coronary Artery Disease Prediction Based on Imaging and Non-Imaging Data.

Authors:  Vassiliki I Kigka; Eleni Georga; Vassilis Tsakanikas; Savvas Kyriakidis; Panagiota Tsompou; Panagiotis Siogkas; Lampros K Michalis; Katerina K Naka; Danilo Neglia; Silvia Rocchiccioli; Gualtiero Pelosi; Dimitrios I Fotiadis; Antonis Sakellarios
Journal:  Diagnostics (Basel)       Date:  2022-06-14

Review 5.  Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory-differentiated thyroid cancer.

Authors:  Paula Jimenez-Fonseca
Journal:  Cancer Med       Date:  2022-10       Impact factor: 4.711

6.  Early L-T4 intervention improves fetal heart development in pregnant rats with subclinical hypothyroidism rats by activating BMP4/Smad4 signaling pathway.

Authors:  D Xue; J L Sun; J Yang
Journal:  BMC Cardiovasc Disord       Date:  2020-08-14       Impact factor: 2.298

7.  Reversible severe tricuspid regurgitation associated with Graves' disease: A case report.

Authors:  Ja-Yeon Lee; Sun Hwa Lee; Won Ho Kim
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

8.  Higher thyrotropin leads to unfavorable lipid profile and somewhat higher cardiovascular disease risk: evidence from multi-cohort Mendelian randomization and metabolomic profiling.

Authors:  Nicolien A van Vliet; Maxime M Bos; Carisha S Thesing; Layal Chaker; Maik Pietzner; Evelyn Houtman; Matt J Neville; Ruifang Li-Gao; Stella Trompet; Rima Mustafa; Fariba Ahmadizar; Marian Beekman; Mariska Bot; Kathrin Budde; Constantinos Christodoulides; Abbas Dehghan; Christian Delles; Paul Elliott; Marina Evangelou; He Gao; Mohsen Ghanbari; Antonius E van Herwaarden; M Arfan Ikram; Martin Jaeger; J Wouter Jukema; Ibrahim Karaman; Fredrik Karpe; Margreet Kloppenburg; Jennifer M T A Meessen; Ingrid Meulenbelt; Yuri Milaneschi; Simon P Mooijaart; Dennis O Mook-Kanamori; Mihai G Netea; Romana T Netea-Maier; Robin P Peeters; Brenda W J H Penninx; Naveed Sattar; P Eline Slagboom; H Eka D Suchiman; Henry Völzke; Ko Willems van Dijk; Raymond Noordam; Diana van Heemst
Journal:  BMC Med       Date:  2021-11-03       Impact factor: 11.150

9.  Usefulness of FT3 to FT4 Ratio to Predict Mortality in Euthyroid Patients With Prior Cardiovascular Events Undergoing PCI: Five-Year Findings From a Large Single-Center Cohort Study.

Authors:  Deshan Yuan; Sida Jia; Pei Zhu; Ce Zhang; Yue Liu; Ru Liu; Jingjing Xu; Xiaofang Tang; Xueyan Zhao; Runlin Gao; Yuejin Yang; Bo Xu; Zhan Gao; Jinqing Yuan
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

10.  Combined use of low T3 syndrome and NT-proBNP as predictors for death in patients with acute decompensated heart failure.

Authors:  Xinke Zhao; Rongcheng Zhang; Hugang Jiang; Kai Liu; Chengxu Ma; Ming Bai; Tao An; Younan Yao; Xinqiang Wang; Ming Wang; Yingdong Li; Yuhui Zhang; Jian Zhang
Journal:  BMC Endocr Disord       Date:  2021-07-02       Impact factor: 2.763

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.